PL1831699T3 - Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek - Google Patents

Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek

Info

Publication number
PL1831699T3
PL1831699T3 PL05820913T PL05820913T PL1831699T3 PL 1831699 T3 PL1831699 T3 PL 1831699T3 PL 05820913 T PL05820913 T PL 05820913T PL 05820913 T PL05820913 T PL 05820913T PL 1831699 T3 PL1831699 T3 PL 1831699T3
Authority
PL
Poland
Prior art keywords
ngal
determination
renal disorders
neutrophil gelatinase
associated lipocalin
Prior art date
Application number
PL05820913T
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Margarita Ghiglione Juanes
Kristian Bangert
Original Assignee
Antibodyshop As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36011033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1831699(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antibodyshop As filed Critical Antibodyshop As
Publication of PL1831699T3 publication Critical patent/PL1831699T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05820913T 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek PL1831699T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63750304P 2004-12-20 2004-12-20
US71930705P 2005-09-21 2005-09-21
EP05820913A EP1831699B1 (en) 2004-12-20 2005-12-20 Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
PCT/DK2005/000806 WO2006066587A1 (en) 2004-12-20 2005-12-20 Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders

Publications (1)

Publication Number Publication Date
PL1831699T3 true PL1831699T3 (pl) 2010-04-30

Family

ID=36011033

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18195687T PL3489689T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń zaburzenie nerki
PL05820913T PL1831699T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18195687T PL3489689T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń zaburzenie nerki

Country Status (18)

Country Link
US (3) US20090170143A1 (pl)
EP (4) EP3208616B1 (pl)
JP (1) JP4741603B2 (pl)
KR (1) KR100971305B1 (pl)
CN (1) CN101163971B (pl)
AT (1) ATE448484T1 (pl)
AU (1) AU2005318689B2 (pl)
CA (1) CA2591113C (pl)
DE (1) DE602005013288D1 (pl)
DK (3) DK3489689T3 (pl)
ES (4) ES2336345T3 (pl)
HK (1) HK1105454A1 (pl)
IL (1) IL183872A (pl)
NZ (1) NZ555926A (pl)
PL (2) PL3489689T3 (pl)
SI (1) SI1831699T1 (pl)
WO (1) WO2006066587A1 (pl)
ZA (1) ZA200705776B (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2739463T3 (es) * 2003-03-27 2020-01-31 Childrens Hospital Med Ct Un método y kit para la detección de la instauración precoz de la lesión de células tubulares renales
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) * 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
EP2602624A1 (en) * 2006-08-07 2013-06-12 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008061149A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for diagnosis and prognosis of renal artery stenosis
EP2500723B1 (en) 2006-11-14 2015-07-08 Alere San Diego, Inc. Methods for monitoring and risk prediction in cardiorenal syndrome
JP5439187B2 (ja) * 2006-12-20 2014-03-12 アンチボディショップ・アクティーゼルスカブ 抗炎症性剤および／または抗凝固剤による治療的介入についての要件を決定するための敗血症患者の評価
JP2010519529A (ja) * 2007-02-23 2010-06-03 プレディクティブ バイオサイエンシーズ コーポレイション 臨床的介入を指向する診断方法
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
CN101910845A (zh) * 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
EP2257813A4 (en) * 2008-03-12 2011-11-02 Univ Columbia NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE
US7977110B2 (en) 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
CN102187220B (zh) 2008-08-28 2015-08-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
JP2012508177A (ja) 2008-11-05 2012-04-05 アボット・ラボラトリーズ 尿および組換えチャイニーズハムスター卵巣（ｃｈｏ）細胞から濃縮された好中球ゼラチナーゼ関連リポカリン（ｎｇａｌ）タンパク質アイソフォーム、ならびに関連する組成物、抗体、ならびに濃縮、分析および使用の方法
AU2009318813B2 (en) * 2008-11-21 2016-11-24 Future Medical Diagnostics Co., Ltd Methods, devices and kits for detecting or monitoring acute kidney injury
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
ES2350078B1 (es) * 2009-05-19 2011-11-15 Consejo Superior De Investigaciones Científicas (Csic) Celula del smf modificada geneticamente para sobreexpresar ngal y su uso como medicamento
WO2010148216A1 (en) * 2009-06-17 2010-12-23 The Trustees Of Columbia University In The City Of New York Methods and compositions for diagnosis of urosepsis and urinary tract infection
CA2770259A1 (en) 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting obstructive uropathy and associated disorders
NZ624609A (en) * 2009-08-28 2015-12-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011053832A1 (en) * 2009-10-29 2011-05-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose sepsis in very low birth weight infants
WO2011084548A2 (en) * 2009-12-15 2011-07-14 King Faisal Specialist Hospital & Research Centre Methods and compositions for detecting recesssive familial fsgs and uses thereof
CN102072960A (zh) * 2010-03-29 2011-05-25 武汉生之源生物科技有限公司 一种样本中中性粒细胞明胶酶相关脂质运载蛋白的检测方法
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
EP3249402A1 (en) * 2010-10-07 2017-11-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102253217B (zh) * 2011-04-07 2013-08-07 武汉生之源生物科技有限公司 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒
TW201250248A (en) * 2011-04-25 2012-12-16 Kyowa Medex Co Ltd Prognostication method of renal failure
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
US20130062516A1 (en) * 2011-09-09 2013-03-14 Hsien-Shou Kuo Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample
WO2013106200A1 (en) * 2012-01-11 2013-07-18 J. Craig Venter Institute Metaproteomic method for diagnosis of bacteriuria, urogenital tract and kidney infections from urinary pellet samples
CN102662064A (zh) * 2012-04-26 2012-09-12 苏州照康生物技术有限公司 检测中性粒细胞明胶酶相关脂质运载蛋白的免疫比浊试剂盒及其制备方法
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CN203441604U (zh) 2013-02-15 2014-02-19 通用电气公司 用于降低燃气涡轮系统中的背压的系统
US9488663B2 (en) 2013-03-14 2016-11-08 Abbott Point Of Care Inc. Electrochemical methods and devices for amending urine samples for immunosensor detection
US9651547B2 (en) 2013-03-14 2017-05-16 Abbott Point Of Care Inc. Electrochemical methods and devices for amending urine samples for immunosensor detection
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
KR101590622B1 (ko) 2013-10-24 2016-02-01 (주)메디컬그룹베스티안 화상 중증도 판단 방법
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
CA2955460A1 (en) 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CN107001455B (zh) * 2014-11-19 2022-03-01 皇家飞利浦有限公司 利用hnl的诊断方法
CN104502596A (zh) * 2014-12-23 2015-04-08 温州医科大学 一种慢性肾病诊断试剂盒
KR101657881B1 (ko) * 2015-03-16 2016-09-19 대구한의대학교산학협력단 타깃 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 급성 및 만성 신장질환 조기진단용 바이오칩
EP3334498B1 (en) 2015-08-12 2023-06-07 The Trustees of Columbia University in the City of New York Methods of treating volume depletion and kidney injury
EP3184116B1 (en) 2015-12-23 2020-09-16 National Taiwan Normal University Neutrophil gelatinase-associated lipocalin for use in prevention or treatment of polycystic kidney disease
TWI581802B (zh) 2015-12-23 2017-05-11 國立臺灣師範大學 嗜中性白血球膠原蛋白質酶相關疏水性蛋白質之製藥用途
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018089693A2 (en) * 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR102094608B1 (ko) * 2018-08-08 2020-04-23 고려대학교 산학협력단 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법
CN109781990A (zh) * 2018-12-25 2019-05-21 无锡市人民医院 一种β-痕迹蛋白检测试剂盒及制备方法
KR102293024B1 (ko) * 2020-02-07 2021-08-24 고려대학교 산학협력단 혈액 종양 질환 특이적 바이오마커

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635091A (en) * 1970-08-31 1972-01-18 Frederick D Linzer Midstream urine specimen and fractional fluid collectors
IT1074038B (it) * 1976-08-05 1985-04-17 Simes Esteri della epinina
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4357343A (en) * 1981-06-26 1982-11-02 Baxter Travenol Laboratories, Inc. Nutritional composition for management of renal failure
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis
JP2912413B2 (ja) * 1990-03-28 1999-06-28 東亜医用電子株式会社 粒度分布作成方法
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
SE9401351D0 (sv) 1994-04-21 1994-04-21 Venge A method for diagnosis
US5552313A (en) * 1994-11-21 1996-09-03 Kansas University DNA encoding mouse phosphotriesterase-related protein
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
ES2258793T5 (es) * 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
EP1009762A2 (en) * 1997-08-06 2000-06-21 ZymoGenetics, Inc. Lipocalin homologs
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
WO2000078919A1 (en) * 1999-06-18 2000-12-28 Michigan State University Method and apparatus for the detection of volatile products in a sample
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
CA2424431A1 (en) * 2000-10-03 2002-04-11 Rowett Research Institute Method of assaying pyrrole-containing biological compounds
US6564385B2 (en) * 2000-10-06 2003-05-20 Mccarthy Daniel J. Handling device
EP1334364A2 (en) * 2000-10-13 2003-08-13 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
FI20010019A (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE10120614A1 (de) 2001-04-26 2002-10-31 Sms Demag Ag Kühlplatte
EP1322957B1 (en) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US6847451B2 (en) * 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
ES2739463T3 (es) * 2003-03-27 2020-01-31 Childrens Hospital Med Ct Un método y kit para la detección de la instauración precoz de la lesión de células tubulares renales
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US7776824B2 (en) * 2004-05-06 2010-08-17 The Trustees Of Columbia University NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
EP2375254A1 (en) * 2006-02-17 2011-10-12 The Children's Medical Center Corporation Free NGAL as a biomarker for cancer
US20080061149A1 (en) * 2006-09-11 2008-03-13 Colin Tanner Proximity payment card with security interlock
US20090123970A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
DE102008025144A1 (de) * 2008-05-26 2009-12-03 Siemens Aktiengesellschaft Anordnung zur Erhöhung der Lese- und Schreibsicherheit von RFID-Labeln

Also Published As

Publication number Publication date
NZ555926A (en) 2008-11-28
IL183872A0 (en) 2007-10-31
CN101163971B (zh) 2013-03-20
WO2006066587A1 (en) 2006-06-29
CN101163971A (zh) 2008-04-16
KR100971305B9 (ko) 2022-07-11
EP1831699B1 (en) 2009-11-11
AU2005318689A1 (en) 2006-06-29
PL3489689T3 (pl) 2020-11-16
DE602005013288D1 (de) 2010-05-06
JP2008524610A (ja) 2008-07-10
IL183872A (en) 2010-11-30
EP3208616B1 (en) 2018-09-26
CA2591113C (en) 2022-06-21
CA2591113A1 (en) 2006-06-29
EP3208616A1 (en) 2017-08-23
SI1831699T1 (sl) 2010-03-31
ZA200705776B (en) 2007-10-31
EP1831699A1 (en) 2007-09-12
DK3489689T3 (da) 2020-09-07
HK1105454A1 (en) 2008-02-15
ES2818028T3 (es) 2021-04-09
KR100971305B1 (ko) 2010-07-20
ATE448484T1 (de) 2009-11-15
JP4741603B2 (ja) 2011-08-03
KR20070108158A (ko) 2007-11-08
DK2128625T3 (en) 2017-05-01
US20160003851A1 (en) 2016-01-07
EP3489689B1 (en) 2020-06-17
EP2128625A3 (en) 2010-07-07
EP2128625B1 (en) 2017-01-25
ES2622467T3 (es) 2017-07-06
US20090170143A1 (en) 2009-07-02
EP2128625A2 (en) 2009-12-02
ES2703434T3 (es) 2019-03-08
ES2336345T3 (es) 2010-04-12
EP3489689A1 (en) 2019-05-29
US20150132772A1 (en) 2015-05-14
DK1831699T3 (da) 2010-03-15
AU2005318689B2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
IL183872A (en) Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
PL2341344T3 (pl) Sposób diagnozowania wielotorbielowatości nerek
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
PL2035835T3 (pl) Sposoby szybkiej oceny ciężkości urazu
MX2009011494A (es) Marcadores de enfermedades.
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2008061149A3 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
WO2006099543A3 (en) Methods for assessing antibody-mediated cytotoxicity
WO2005121366A8 (ja) 遺伝子マーカー及びその利用
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
BRPI0512655A (pt) bioexame de rna
WO2007075672A3 (en) Prognostic cancer markers
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
MX2011007810A (es) Biomarcadores asociados con nefropatia.
WO2008099608A1 (ja) 炎症性腸疾患の診断方法
NZ590993A (en) Dual specificity phosphatase 1 protein (DUSP1) for diagnosis and prognosis of skin cancer
WO2004038377A3 (en) Method for diagnosing renal diseases or predispositions
WO2009022632A1 (ja) 新規肝癌マーカー
WO2009122367A3 (en) Procollagen c-proteinase enhancer (pcpe) biomarker for bone formation
ATE532064T1 (de) Genmarker und dessen verwendung